Roche’s Enicepatide Shows Superior Diabetes Control vs. Lilly’s Retatrutide in Phase 2 Trial
Roche reported that its dual GLP-1/GIP agonist enicepatide met primary endpoints in a phase 2 trial for type 2 diabetes, showing greater HbA1c reduction and weight loss than competitors at similar timepoints. The data supports Roche’s push to become a top-three obesity player despite analyst skepticism about Lilly’s dominance.